1. Home
  2. ASMB vs PFO Comparison

ASMB vs PFO Comparison

Compare ASMB & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • PFO
  • Stock Information
  • Founded
  • ASMB 2005
  • PFO 1991
  • Country
  • ASMB United States
  • PFO United States
  • Employees
  • ASMB 73
  • PFO N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • PFO Finance Companies
  • Sector
  • ASMB Health Care
  • PFO Finance
  • Exchange
  • ASMB Nasdaq
  • PFO Nasdaq
  • Market Cap
  • ASMB 198.6M
  • PFO 121.4M
  • IPO Year
  • ASMB 2010
  • PFO N/A
  • Fundamental
  • Price
  • ASMB $25.50
  • PFO $9.29
  • Analyst Decision
  • ASMB Strong Buy
  • PFO
  • Analyst Count
  • ASMB 4
  • PFO 0
  • Target Price
  • ASMB $38.67
  • PFO N/A
  • AVG Volume (30 Days)
  • ASMB 147.2K
  • PFO 31.8K
  • Earning Date
  • ASMB 08-06-2025
  • PFO 01-01-0001
  • Dividend Yield
  • ASMB N/A
  • PFO 6.51%
  • EPS Growth
  • ASMB N/A
  • PFO N/A
  • EPS
  • ASMB N/A
  • PFO N/A
  • Revenue
  • ASMB $33,247,000.00
  • PFO N/A
  • Revenue This Year
  • ASMB $12.44
  • PFO N/A
  • Revenue Next Year
  • ASMB N/A
  • PFO N/A
  • P/E Ratio
  • ASMB N/A
  • PFO N/A
  • Revenue Growth
  • ASMB 54.77
  • PFO N/A
  • 52 Week Low
  • ASMB $7.75
  • PFO $6.90
  • 52 Week High
  • ASMB $27.17
  • PFO $8.51
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 65.04
  • PFO 54.71
  • Support Level
  • ASMB $24.98
  • PFO $9.19
  • Resistance Level
  • ASMB $27.17
  • PFO $9.31
  • Average True Range (ATR)
  • ASMB 1.13
  • PFO 0.06
  • MACD
  • ASMB -0.06
  • PFO -0.01
  • Stochastic Oscillator
  • ASMB 64.24
  • PFO 55.56

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

Share on Social Networks: